Journal of gastroenterology and hepatology · 2026
Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Neo Klarisse Man Ling, How Alicia Le, Ang Asher Yu Han, Pang Gheng Yong, Patil Shruti Rahul, Tan Hua Wang, Zhou Kevin Xiang, Siah Kewin Tien Ho, Ng Qin Xiang
Аннотация
BACKGROUND AND AIM: Given the prevalence and chronicity of irritable bowel syndrome (IBS), this systematic review aimed to synthesize evidence on the cost of illness of IBS, with attention to the relative contributions of direct healthcare and indirect non-healthcare costs.
METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted from inception to August 2025, following PRISMA 2020 guidelines (PROSPERO CRD420251266432). Studies were included if they primarily assessed costs of IBS with sufficiently detailed methodology. Costs were inflation-adjusted to 2024 US dollars using World Bank consumer price indices and prevailing exchange rates. Risk of bias was assessed using the Consensus on Health Economic Criteria (CHEC) list.
RESULTS: Thirty-three studies met our inclusion criteria, spanning 14 countries from 1992 to 2022. Mean annual direct healthcare costs per patient ranged widely, from US$193 in Korea to US$31113 in the United States among patients with IBS-C. Among the 10 studies adopting a societal perspective, indirect costs such as absenteeism, presenteeism, and lost productivity frequently constituted a dominant share of total costs. In some settings, non-healthcare costs exceeded direct healthcare costs several-fold (e.g., Sweden: US$17112 vs. US$1943 for IBS-C). Treatment failure and inadequate symptom control were associated with higher expenditures. IBS-C incurred the highest subtype-specific costs, and racial and gender disparities in spending were identified.
CONCLUSIONS: IBS imposes a considerable global economic burden. When societal perspectives are adopted, indirect costs emerge as a predominant driver of total costs, necessitating holistic management strategies. Importantly, assessments limited to direct healthcare expenditures underestimate the true economic impact of IBS.
METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted from inception to August 2025, following PRISMA 2020 guidelines (PROSPERO CRD420251266432). Studies were included if they primarily assessed costs of IBS with sufficiently detailed methodology. Costs were inflation-adjusted to 2024 US dollars using World Bank consumer price indices and prevailing exchange rates. Risk of bias was assessed using the Consensus on Health Economic Criteria (CHEC) list.
RESULTS: Thirty-three studies met our inclusion criteria, spanning 14 countries from 1992 to 2022. Mean annual direct healthcare costs per patient ranged widely, from US$193 in Korea to US$31113 in the United States among patients with IBS-C. Among the 10 studies adopting a societal perspective, indirect costs such as absenteeism, presenteeism, and lost productivity frequently constituted a dominant share of total costs. In some settings, non-healthcare costs exceeded direct healthcare costs several-fold (e.g., Sweden: US$17112 vs. US$1943 for IBS-C). Treatment failure and inadequate symptom control were associated with higher expenditures. IBS-C incurred the highest subtype-specific costs, and racial and gender disparities in spending were identified.
CONCLUSIONS: IBS imposes a considerable global economic burden. When societal perspectives are adopted, indirect costs emerge as a predominant driver of total costs, necessitating holistic management strategies. Importantly, assessments limited to direct healthcare expenditures underestimate the true economic impact of IBS.